Abstract :
[en] Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic
stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter
aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres.
Methods
and results
Patients with severe aortic stenosis at a higher surgical risk inwhomimplantation of theCoreValve Systemwas decided by
the Heart Teamwere included. Endpointswere a composite of major adverse cardiovascular and cerebrovascular events
(MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint-
related eventswere independently adjudicated based on Valve AcademicResearch Consortiumdefinitions.Atotal
of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years]
were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase
in the effective aortic valve orifice area. At 30 days, theMACCErate was 8.0% (95% CI: 6.3–9.7%), all-cause mortalitywas
4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The lifethreatening
or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular
mortality, and stroke were 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%),
respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro-
SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P , 0.05), respectively.
Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke
rates in higher risk real-world patients with severe aortic stenosis.
Scopus citations®
without self-citations
128